Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Farhad Kazazi
Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors
JAMA Oncology
Cancer Research
Oncology
Related publications
Phase I Study of Nivolumab, an Anti-Pd-1 Antibody, in Patients With Malignant Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
O3-2-5a Phase I Trial of BI 754091, a Programmed Death Receptor 1 (PD-1) Inhibitor, in Patients With Advanced Solid Tumors
Annals of Oncology
Medicine
Oncology
Hematology
Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-Il-23 Monoclonal Antibody, Following Intravenous or Subcutaneous Administration in Healthy Subjects
Basic and Clinical Pharmacology and Toxicology
Medicine
Toxicology
Pharmacology
A Phase 1 Study of Oral Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Oncotarget
Oncology
Avelumab, an Anti-Pd-L1 Antibody, in Patients With Locally Advanced or Metastatic Breast Cancer: A Phase 1b JAVELIN Solid Tumor Study
Breast Cancer Research and Treatment
Cancer Research
Oncology
Relationship Between Immune Gene Signatures and Clinical Response to PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Advanced Solid Tumors
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology